{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:08:24Z","timestamp":1790791704553,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Precision"},{"name":"Sigrid Juselius Foundation"},{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007798","name":"Research Foundation of the University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007798","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Faculty of Pharmacy, Helsinki University"},{"name":"European Research Council"},{"name":"ERC","award":["681219"],"award-info":[{"award-number":["681219"]}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"crossref","award":["4705796"],"award-info":[{"award-number":["4705796"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"crossref","award":["797011004"],"award-info":[{"award-number":["797011004"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Finnish Foundation","award":["4706116"],"award-info":[{"award-number":["4706116"]}]},{"DOI":"10.13039\/501100004155","name":"Magnus Ehrnrooth Foundation","doi-asserted-by":"crossref","award":["4706235"],"award-info":[{"award-number":["4706235"]}],"id":[{"id":"10.13039\/501100004155","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the success of immune checkpoint inhibitors against PD-L1 in the clinic, only a fraction of patients benefit from such therapy. A theoretical strategy to increase efficacy would be to arm such antibodies with Fc-mediated effector mechanisms. However, these effector mechanisms are inhibited or reduced due to toxicity issues since PD-L1 is not confined to the tumor and also expressed on healthy cells. To increase efficacy while minimizing toxicity, we designed an oncolytic adenovirus that secretes a cross-hybrid Fc-fusion peptide against PD-L1 able to elicit effector mechanisms of an IgG1 and also IgA1 consequently activating neutrophils, a population neglected by IgG1, in order to combine multiple effector mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cross-hybrid Fc-fusion peptide comprises of an Fc with the constant domains of an IgA1 and IgG1 which is connected to a PD-1 ectodomain via a GGGS linker and was cloned into an oncolytic adenovirus. We demonstrated that the oncolytic adenovirus was able to secrete the cross-hybrid Fc-fusion peptide able to bind to PD-L1 and activate multiple immune components enhancing tumor cytotoxicity in various cancer cell lines, in vivo and ex vivo renal-cell carcinoma patient-derived organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using various techniques to measure cytotoxicity, the cross-hybrid Fc-fusion peptide expressed by the oncolytic adenovirus was shown to activate Fc-effector mechanisms of an IgA1 (neutrophil activation) as well as of an IgG1 (natural killer and complement activation). The activation of multiple effector mechanism simultaneously led to significantly increased tumor killing compared with FDA-approved PD-L1 checkpoint inhibitor (Atezolizumab), IgG1-PDL1 and IgA-PDL1 in various in vitro cell lines, in vivo models and ex vivo renal cell carcinoma organoids. Moreover, in vivo data demonstrated that Ad-Cab did not require CD8+ T cells, unlike conventional checkpoint inhibitors, since it was able to activate other effector populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Arming PD-L1 checkpoint inhibitors with Fc-effector mechanisms of both an IgA1 and an IgG1 can increase efficacy while maintaining safety by limiting expression to the tumor using oncolytic adenovirus. The increase in tumor killing is mostly attributed to the activation of multiple effector populations rather than activating a single effector population leading to significantly higher tumor killing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-003000","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T12:11:21Z","timestamp":1628251881000},"page":"e003000","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-7382","authenticated-orcid":false,"given":"Firas","family":"Hamdan","sequence":"first","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9678-2614","authenticated-orcid":false,"given":"Erkko","family":"Yl\u00f6sm\u00e4ki","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Giannoula","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Long","sequence":"additional","affiliation":[{"name":"Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-3018","authenticated-orcid":false,"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-4310","authenticated-orcid":false,"given":"Sara","family":"Feola","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Feodoroff","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Antignani","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Kari","sequence":"additional","affiliation":[{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Nisen","sequence":"additional","affiliation":[{"name":"Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kreutzman","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4982-6914","authenticated-orcid":false,"given":"Jeanette","family":"Leusen","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, UMC Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland"},{"name":"Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G","family":"McWilliams","sequence":"additional","affiliation":[{"name":"Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland"},{"name":"Department of Anatomy, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland"},{"name":"TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland"},{"name":"Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland"},{"name":"Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University 24 Federico II, 80131, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"2025100309012859000_9.8.e003000.1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2025100309012859000_9.8.e003000.2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100309012859000_9.8.e003000.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6583-3","article-title":"Current status of the clinical use of PD-1\/PD-L1 inhibitors: a questionnaire survey of oncologists in China","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"2025100309012859000_9.8.e003000.4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025100309012859000_9.8.e003000.5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2025100309012859000_9.8.e003000.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-Binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2025100309012859000_9.8.e003000.7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.coi.2016.03.002","article-title":"Immunoglobulin isotype knowledge and application to Fc engineering","volume":"40","author":"Brezski","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2025100309012859000_9.8.e003000.8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-Dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"2025100309012859000_9.8.e003000.9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"2025100309012859000_9.8.e003000.10","doi-asserted-by":"crossref","unstructured":"Goletz C , Lischke T , Harnack U , et al . Glyco-engineered anti-human programmed death-ligand 1 antibody mediates stronger CD8 T cell activation than its normal glycosylated and non-glycosylated counterparts. Front Immunol 2018;9.doi:10.3389\/fimmu.2018.01614","DOI":"10.3389\/fimmu.2018.01614"},{"key":"2025100309012859000_9.8.e003000.11","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0045-2016","article-title":"The role and function of Fc\u03b3 receptors on myeloid cells","volume":"4","author":"Bournazos","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2025100309012859000_9.8.e003000.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03124","article-title":"Fc\u03b3riiib restricts antibody-dependent destruction of cancer cells by human neutrophils","volume":"9","author":"Treffers","year":"2018","journal-title":"Front Immunol"},{"key":"2025100309012859000_9.8.e003000.13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4161\/mabs.27457","article-title":"Increasing Fc\u03b3RIIa affinity of an Fc\u03b3RIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity","volume":"6","author":"Derer","year":"2014","journal-title":"MAbs"},{"key":"2025100309012859000_9.8.e003000.14","doi-asserted-by":"crossref","unstructured":"Brandsma AM , Bondza S , Evers M , et al . Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front Immunol 2019;10.doi:10.3389\/fimmu.2019.00704","DOI":"10.3389\/fimmu.2019.00704"},{"key":"2025100309012859000_9.8.e003000.15","doi-asserted-by":"crossref","first-page":"25139","DOI":"10.1074\/jbc.M112.353060","article-title":"Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages","volume":"287","author":"Lohse","year":"2012","journal-title":"J Biol Chem"},{"key":"2025100309012859000_9.8.e003000.16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1040-8428(01)00105-6","article-title":"Iga antibodies for cancer therapy","volume":"39","author":"Dechant","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100309012859000_9.8.e003000.17","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/2326-6066.CIR-15-0099-T","article-title":"Simultaneous targeting of Fc\u03b3Rs and Fc\u03b1RI enhances tumor cell killing","volume":"3","author":"Brandsma","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2025100309012859000_9.8.e003000.18","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.chembiol.2014.10.017","article-title":"IgGA: A \u201ccross-isotype\u201d engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions","volume":"21","author":"Kelton","year":"2014","journal-title":"Chem Biol"},{"key":"2025100309012859000_9.8.e003000.19","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure-Response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025100309012859000_9.8.e003000.20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther"},{"key":"2025100309012859000_9.8.e003000.21","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.mt.6300223","article-title":"Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses","volume":"15","author":"H\u00f6ti","year":"2007","journal-title":"Mol Ther"},{"key":"2025100309012859000_9.8.e003000.22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol Ther"},{"key":"2025100309012859000_9.8.e003000.23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol Ther"},{"key":"2025100309012859000_9.8.e003000.24","doi-asserted-by":"crossref","first-page":"625-634","DOI":"10.1016\/j.omtm.2021.01.014","article-title":"GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses","volume":"20","author":"Hamdan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100309012859000_9.8.e003000.25","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100309012859000_9.8.e003000.26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2326-6066.CIR-19-0144","article-title":"IgA-Mediated killing of tumor cells by neutrophils is enhanced by CD47\u2013SIRPA checkpoint inhibition","volume":"8","author":"Treffers","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2025100309012859000_9.8.e003000.27","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill Antibody-Opsonized cancer cells by Trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep"},{"key":"2025100309012859000_9.8.e003000.28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100309012859000_9.8.e003000.29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433981","article-title":"Pd-1\/Pd-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100309012859000_9.8.e003000.30","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100309012859000_9.8.e003000.31","doi-asserted-by":"crossref","unstructured":"Yu W , Wang Y , Jiang Y , et al . Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases. BMC Cancer 2017;17.doi:10.1186\/s12885-017-3275-8","DOI":"10.1186\/s12885-017-3275-8"},{"key":"2025100309012859000_9.8.e003000.32","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"key":"2025100309012859000_9.8.e003000.33","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"2025100309012859000_9.8.e003000.34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2025100309012859000_9.8.e003000.35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.yexcr.2011.03.018","article-title":"Modulation of antibody effector function","volume":"317","author":"Desjarlais","year":"2011","journal-title":"Exp Cell Res"},{"key":"2025100309012859000_9.8.e003000.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01958","article-title":"Expression, role, and regulation of neutrophil Fc\u03b3 receptors","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"2025100309012859000_9.8.e003000.37","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2008-03-144600","article-title":"Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells","volume":"112","author":"Peipp","year":"2008","journal-title":"Blood"},{"key":"2025100309012859000_9.8.e003000.38","doi-asserted-by":"crossref","first-page":"21248","DOI":"10.1073\/pnas.1015855107","article-title":"Granulocyte-Colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes","volume":"107","author":"Kowanetz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100309012859000_9.8.e003000.39","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1073\/pnas.1424927112","article-title":"Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils","volume":"112","author":"Casbon","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100309012859000_9.8.e003000.40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"Il-17-Producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"2025100309012859000_9.8.e003000.41","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/cas.13627","article-title":"Tumor-Infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci"},{"key":"2025100309012859000_9.8.e003000.42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ymeth.2013.06.020","article-title":"Myeloid cells as effector cells for monoclonal antibody therapy of cancer","volume":"65","author":"Braster","year":"2014","journal-title":"Methods"},{"key":"2025100309012859000_9.8.e003000.43","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2013-04-497446","article-title":"Neutrophils mediate antibody-induced antitumor effects in mice","volume":"122","author":"Albanesi","year":"2013","journal-title":"Blood"},{"key":"2025100309012859000_9.8.e003000.44","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"2025100309012859000_9.8.e003000.45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2025100309012859000_9.8.e003000.46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2019.05.005","article-title":"Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors","volume":"154","author":"Maru","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025100309012859000_9.8.e003000.47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"2025100309012859000_9.8.e003000.48","doi-asserted-by":"crossref","unstructured":"Fusco P , Parisatto B , Rampazzo E , et al . Patient-Derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours. BMC Cancer 2019;19.doi:10.1186\/s12885-019-6149-4","DOI":"10.1186\/s12885-019-6149-4"},{"key":"2025100309012859000_9.8.e003000.49","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ymthe.2005.06.443","article-title":"Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer","volume":"12","author":"Heideman","year":"2005","journal-title":"Molecular Therapy"},{"key":"2025100309012859000_9.8.e003000.50","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1084\/jem.20171093","article-title":"Zika virus has oncolytic activity against glioblastoma stem cells","volume":"214","author":"Zhu","year":"2017","journal-title":"J Exp Med"}],"updated-by":[{"DOI":"10.1136\/jitc-2021-003000corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:01:41Z","timestamp":1759507301000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,6]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/jitc-2021-003000"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003000","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}